Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexpropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL9064508 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL29349844 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL17838091 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL41688 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Levopropranolol SCHEMBL41689 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL1553064 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Dexpropranolol SCHEMBL30309315 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Levopropranolol SCHEMBL30530984 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL9183224 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL7397696 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | claimed |
| CN-102232088-A | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | SCHERING CORP | 2011-11-02 | — | — | CN | claimed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| WO-1991005553-A1 | USE OF D-PROPRANOLOL AGAINST SEXUALLY TRANSMITTED BACTERIA | FAMILY HEALTH INTERNATIONAL (US) | 1991-05-02 | — | — | WO | claimed |
| US-4988736-A | Bactericides against gonococci | FAMILY HEALTH INTERNATIONAL (US) | 1991-01-29 | — | — | US | claimed |
| WO-1989003209-A1 | CONTRACEPTIVE COMPOSITION COMPRISING NONOXYNOL-9, AND D-PROPRANOLOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FAMILY HEALTH INTERNATIONAL (US) | 1989-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ADRB2 4211/4885ADRB1 3264/4885ADRB3 2783/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRB2 346/4885ADRB1 193/4885ADRB3 264/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ADRB2 4211/4885ADRB1 3264/4885ADRB3 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.